Parkinson Clinical Trial
Official title:
The Effect of Color Therapy on Quality of Life, Anxiety and Fatigue Levels of Parkison Patients
The aim of this study was to investigate the effect of color therapy on quality of life, anxiety and fatigue levels in patients with Parkinson's disease.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | June 27, 2024 |
Est. primary completion date | April 27, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Having been diagnosed with Parkinson's disease for at least 6 months, - Those who have not taken sleeping pills or sedative drugs, - Not having undergone brain stimulation surgery, - Do not have a physical illness or cognitive disability that would prevent them from understanding the education provided, and do not have a diagnosis of a psychiatric disease, - According to the Parkinson's Fatigue Scale, the scale score is >8 - The patient or someone living in the same house with the patient is literate, - Patients have no vision problems. Exclusion Criteria: - Parkinson patients who did not agree to participate in the research |
Country | Name | City | State |
---|---|---|---|
Turkey | Firat University | Elazig |
Lead Sponsor | Collaborator |
---|---|
Ataturk University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quality of Life Scale (SF36) | It was developed to measure the quality of life in people with physical diseases. It is measured in 8 dimensions and 36 items: physical function, physical role difficulty, emotional role difficulty, viability, mental health, social functionality, pain, and general health perception. | At the end of Color Therapy (therapy 9 times in total in 3 months) | |
Primary | Beck Anxiety Inventory (BAI) | It consists of 21 questions and a minimum score of 0 and a maximum score of 3 is obtained from each question. As a result of the answers to all questions, all answers are summed up and a total score is obtained. In the evaluation phase, the presence and level of depression is interpreted in line with the meanings expressed by the score ranges. In the evaluation, 0-9 point range defines the presence of minimal depressive symptoms, 10-16 point range defines the presence of mild depressive symptoms, 17-29 point range defines the presence of moderate depressive symptoms and 30-63 point range defines the presence of severe depressive symptoms. A score of 17 and above indicates a level of depression that may require treatment. | At the end of Color Therapy (therapy 9 times in total in 3 months) | |
Primary | Parkinson's Fatigue Scale (PYO-16) | It consists of 16 items, with 5 responses for each item (1=strongly disagree, 5=strongly agree). The result evaluation can be done in two different ways. The total value is calculated as the average of the response to all items (value range 1-5). Scores above the average "3.3" are considered tired. In the other rating option, 0 (actual response 1-3) and 1 (actual response 4-5) are scored, with a total value between 0-16. A total of 8 points and above is considered tired. In both methods, a higher value indicates a higher level of fatigue. | At the end of Color Therapy (therapy 9 times in total in 3 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06037590 -
A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops™ Relative to INBRIJA®
|
Phase 1 | |
Recruiting |
NCT01537224 -
Electrophysiological Activity of the Subthalamic Nucleus During the Processing of Emotional and Motivational Information
|
N/A | |
Withdrawn |
NCT04011449 -
State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S
|
N/A | |
Completed |
NCT02539446 -
Suprapostural Attention Focus and Postural Difficulty on H-reflex and Brain Activity: Aging and Parkinson's Disease
|
N/A | |
Completed |
NCT00358189 -
Effects of Deep Brain Stimulation for the Treatment of Parkinson's Disease
|
N/A | |
Active, not recruiting |
NCT04606979 -
tDCS of the Primary Motor Cortex to Improve Implicit Motor Sequence Learning in Parkinson's Disease
|
N/A | |
Completed |
NCT05119803 -
The Relationship of Spine Posture and Mobility With Upper Extremity Functions in Parkinson's Patients
|
||
Not yet recruiting |
NCT02249715 -
Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease
|
N/A | |
Completed |
NCT01732653 -
A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults
|
N/A | |
Completed |
NCT03232996 -
Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease.
|
N/A | |
Enrolling by invitation |
NCT04566341 -
Study of Gastrointestinal Dysfunction and Enteric Neural Pathology in Patients With Parkinson's Disease
|
||
Active, not recruiting |
NCT04978597 -
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)
|
Phase 3 | |
Recruiting |
NCT06116084 -
Randomized Controlled Study Evaluating the Efficacy of Hypnosis in Nuclear Medicine
|
N/A | |
Recruiting |
NCT05830396 -
GRoningen Early-PD Ambroxol Treatment
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05379062 -
Choral Singing for Patients With Parkinson's
|
N/A | |
Completed |
NCT02071823 -
Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules
|
Phase 1 | |
Recruiting |
NCT03558568 -
The Effect of Deep Brain Stimulation on Facial Expressions.
|
N/A | |
Enrolling by invitation |
NCT05596201 -
Super-resolution of Brain Magnetic Resonance Images in Deep Brain Stimulation for Parkinson's Disease
|
||
Recruiting |
NCT04181918 -
Action Observation Treatment in Parkinson's Patients
|
N/A | |
Completed |
NCT02305277 -
Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers
|
Phase 1 |